Talis Biomedical Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-62.01	-113.01	-192.04	-91.13	26.38	Upgrade
Depreciation & Amortization	5.07	11.6	2.62	1.37	0.73	Upgrade
Share-Based Compensation	4.35	5.37	9.21	3.68	0.97	Upgrade
Other Operating Activities	-0.66	-4.09	8.82	-0.95	1.46	Upgrade
Operating Cash Flow	-53.24	-100.14	-171.38	-87.02	-24.33	Upgrade
Capital Expenditures	-0.49	-1.62	-2.87	-8.2	-0.58	Upgrade
Investing Cash Flow	-0.49	-1.62	-2.87	-8.2	-0.58	Upgrade
Share Issuance / Repurchase	0.03	0.41	234.43	-1.44	0.02	Upgrade
Debt Issued / Paid	0	0	0	0	15	Upgrade
Other Financing Activities	-	-	-	248.19	24.59	Upgrade
Financing Cash Flow	0.03	0.41	234.43	246.75	39.61	Upgrade
Net Cash Flow	-53.69	-101.35	60.18	151.53	14.71	Upgrade
Free Cash Flow	-53.73	-101.75	-174.25	-95.23	-24.9	Upgrade
Free Cash Flow Margin	-2517.62%	-2114.53%	-2126.82%	-870.59%	-626.20%	Upgrade
Free Cash Flow Per Share	-29.56	-56.51	-115.37	-673.66	-486.17	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).